LIBRE LIFE LATEST NEWS

Summer 2026 has brought important developments across FreeStyle Libre, from Libre 3 Plus and rapid growth in hybrid closed-loop use to new ADA evidence supporting Libre Duo, AI-powered Libre Assist and Abbott's wider move into connected health.

Dexcom's latest announcements aren't just about a smaller sensor or longer wear. From G8 and hybrid closed-loop technology to Stelo, digital health and the wider CGM community, Summer 2026 reveals a company whose ambitions increasingly extend beyond diabetes sensors and towards a connected health platform.

Insulet's latest Omnipod 6 announcements go beyond a smarter insulin pump. New clinical data and fresh insights into fully closed-loop technology reveal how the company hopes to reduce the daily burden of living with diabetes while raising important questions about automation, data and control.

For years, type 2 diabetes has been linked to carrying too much body fat. But new research suggests the story may be more complicated. According to scientists, it's not just how much fat you have that matters. It's whether your body can still use it properly.

A research smart ring can monitor glucose and ketones from sweat continuously. It's an exciting step, but it remains a long way from replacing CGMs.

A newly published correspondence in The Lancet Diabetes & Endocrinology has now reopened a debate that many healthcare systems believed had largely been settled: does wider CGM adoption always represent good value?

Wearable technology is becoming increasingly visible in professional tennis. From WHOOP recovery bands and continuous glucose monitors to Abbott's Lingo biosensor, here's who's wearing what at Wimbledon 2026 and why these devices are attracting attention both on and off the court.

From WHOOP straps and smart rings to the growing number of people wearing sensors on their upper arms, wearable health technology is becoming impossible to ignore. Lewis Hamilton, Harry Kane, Ollie Watkins and other elite athletes are helping drive a trend that is rapidly moving from professional sport into everyday life.

Teplizumab becomes the first NHS-approved treatment shown to delay the onset of type 1 diabetes. Given as a 14-day course of infusions before symptoms develop, the drug could postpone diagnosis by around two to three years and may signal the beginning of a new era in type 1 diabetes treatment.

Dexcom has agreed to acquire Nutrisense, bringing nutrition coaching and metabolic health services into its growing ecosystem. The deal offers the clearest sign yet that the future of CGM could extend far beyond traditional diabetes management.

EOFlow has secured a significant legal victory after a US appeals court overturned a $59.4 million judgment awarded to Insulet in the long-running dispute between the two patch pump manufacturers.